AGÑÇÓ鼯ÍŹٷ½ÍøÕ¾

ÄúÏÖÔÚµÄλÖãº ÍøÕ¾Ê×Ò³>´ÙÏúÖÐÐÄ

×Ô»¥²¹AAV£¨scAAV£©¡ª¡ª¿ìËÙ¡¢¸ßЧ¡¢³¤Ê±±í´ïÔØÌå

2022-03-03

ÖØ×éÏÙÏà¹Ø²¡¶¾£¨ Recombinant adeno-associated virus, rAAV£©ÊÇÒ»ÖÖÎÞ°üĤ¡¢ÒÔµ¥Á´DNAΪÒÅ´«ÎïÖÊ¡¢»ùÒò×éÈÝÁ¿4.7kbµÄ¸´ÖÆÈ±ÏÝÐÍ΢С²¡¶¾¡£rAAV¾ßÓжàÖÖѪÇåÐÍ¿ÉÇ×ÊȲ»Í¬°ÐÆ÷¹Ù£¬ÃâÒßÔ­ÐÔ¼«µÍ°²È«ÐԸߣ¬2-3Öܿɴﵽ±í´ï¸ß·åÇÒ³¤Ê±¼äÎȶ¨±í´ïµÈÌØµã£¬Òò´Ë£¬rAAV¹ã·ºÓ¦ÓÃÓÚ¶¯ÎïÑо¿¡¢»ù´¡Ñо¿ºÍ»ùÒòÖÎÁÆÁìÓò¡£
AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾

×Ô»¥²¹AAV£¨Self-complementary AAV, scAAV£©ÔÚrAAVµÄ»ù´¡ÉϽ«Æä±àÂëÇøÓòÉè¼Æ³ÉË«Á´DNA£¬Òò´ËscAAV¸ÐȾϸ°ûºó»¥²¹²¿·Ö»¥²¹ÐγÉË«Á´DNA£¬È»ºó½øÐÐת¼¡¢·­Ò룬²»ÐèµÈ´ýµÚ¶þÁ´DNAºÏ³É£¬È¡ÏûÁËrAAV»ùÒò±í´ïµÄÏÞËÙ²½Ö裬Ëõ¶ÌÁË¿ªÊ¼±í´ïµÄʱ¼ä£¬scAAV¸ÐȾºóÒ»°ã3-5Ìì¼´¿Éµ½´ï±í´ï¸ß·å¡£µ«Ò²ÕýÊÇscAAVµÄË«Á´DNA½á¹¹£¬ÖÂʹÆäÈÝÁ¿ËõСÖÁ2.1kb£¬Òò´ËÍâÔ´Ä¿µÄ»ùÒò´óСÐèÒª¿ØÖÆÔÚ1kb×óÓÒ¡£
AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾
ͼ1 ssAAVÓëscAAV¸ÎÔà±í´ï£¨1E+11 VG/Ö»£¬Î²¾²Âö×¢É䣩



×Ô»¥²¹AAVÓ¦ÓÃÁìÓò



1. ¸ÉÈŰеãɸѡ

¶Ì·¢¼ÐRNA£¨Short hairpin RNA, shRNA£©¿Ë¡½ø²¡¶¾ÔØÌå¸ÐȾϸ°ûºó£¬ÔÚϸ°ûÖбí´ïС¸ÉÈÅRNA£¨Small interfering RNA, siRNA£©£¬ÒÖÖÆmRNAת¼£¬ÊµÏÖÒÖÖÆÄ¿µÄ»ùÒò±í´ïÄ¿µÄ¡£¶ÔÓÚδ֪µÄ¸ÉÈŰлùÒòµÄɸѡһ°ã²ÉÈ¡ÌåÍâʵÑéµÄ·½Ê½½øÐÐÑéÖ¤£¬ÔÚϸ°ûϵÉϽøÐÐÑé֤ʱ³£»áÓöµ½ÌåÍâÓÐЧ¹ûÌåÄÚÎÞЧ¹ûµÄÇé¿ö£»»òÔÚÔ­´úϸ°ûÉÏÑéÖ¤£¬Ô­´úϸ°û·ÖÀëÄѶȴó¡¢ÅàÑøÄѶȸßҲͬÑùÖÆÔ¼ÁËshRNAµÄ°Ð»ùÒòЧ¹ûÑéÖ¤£»³£¹æÌåÄÚɸѡ°ÐµãµÄ·½Ê½ÓÖ´ó´óµÄÓ°ÏìÁËÑо¿µÄËÙ¶È¡£È»¶ø£¬scAAV-shRNAɸѡ¸ÉÈŰеã¿ÉÒÔ¿ìËÙ²¢ÇÒ׼ȷµØ»ñµÃ¸ÉÈŽá¹û£¬¼«´óµÄ¼Ó¿ìÁËÑо¿µÄЧÂÊ¡£
AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾

2. »ùÒò±à¼­

CRISPR/Cas9¼¼Êõͨ¹ý¶Ô»ùÒòˮƽ²Ù×÷ʵÏÖ»ùÒòÇóý»ò»ùÒò¶¨µã±à¼­¡£ÀûÓò¡¶¾ÔØÌå±í´ïÏòµ¼RNA£¨guide RNA, gRNA£©£¬ÅäºÏCas9СÊó/²¡¶¾£¬¿ÉÒÔ¶ÔСÊóµÄÄ¿µÄ»ùÒò½øÐб༭¡£
AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾
ͼ3 ¼¡Èâ×¢ÉäAAV9»ùÒò±à¼­Ôª¼þ´«µÝµ½D52 DMDСÊó¸ÄÉÆÓªÑø²»Á¼µ°°×±í´ï
£¨Min Y L, et al., Molecular Therapy, 2020£©



3. »ùÒòÇýµ

Cre-LoxPÖØ×éøÌåϵÒòÆäÌØÒìÐÔÖÊ£¬¹ã·ºÓ¦ÓÃÔÚ»ùÒòÇóý£¨Knock out£¬KO£©»òÇÃÈ루Knock in£¬KI£©Ñо¿ÖУ¬Ä¿Ç°³£ÓÃת»ùÒòСÊóÀ´ÊµÏÖ¡£×ª»ùÒòСÊóÓÉÓÚ¹¹½¨ÖÜÆÚ³¤£¬¼Û¸ñ¸ß£¬·±Óýʱ¼ä¾Ã£¬²¿·Ö»ùÒòÇóý»ò¹ý±í´ïÅßÌ¥ÖÂËÀµÈÔ­ÒòÖÆÔ¼ÁËÑо¿µÄ˳Àû½øÐУ¬È»¶ø£¬²¡¶¾ÔØÌå¿ÉÒÔ¿Ë·þÒÔÉÏÑо¿ÖгöÏÖµÄÎÊÌâ¡£scAAV-creÅäºÏFloxСÊóʹÓ㬿ÉÔÚ³ÉÄê»òÓ×ÄêСÊóÉÏʵÏÖ¿ìËÙ»ùÒòÇýµ£¨Knock down, KD£©¡£

AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾

4. ÌØÒìÐÔ±ê¼Ç

ÁíÍ⣬ÀûÓÃCreСÊó»òscAAV-CreÅäºÏscAAV-DIOʵÏÖ¸ü¼Ó¾«Ï¸¡¢¿ìËÙµÄϸ°û±ê¼Ç¡£

AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾
ͼ5 scAAV-FLEx-mRuby2Ó«¹âµ°°×ÔÚHVC(X)ϸ°ûȺÖÐÏÞÖÆÐÔ±í´ï
£¨S¨¢nchez-Valpuesta M, et al.,PNAS, 2019£©



5. ¹ý±í´ï

ÀûÓÃscAAV¹ý±í´ïÄ¿µÄ»ùÒò¿ÉÒÔʵÏÖ¸ÄÄ¿µÄ»ùÒòÔÚÌåÄÚ¿ìËÙ±í´ïµÄÄ¿µÄ£¬µ«ÊÇÖµµÃ×¢ÒâµÄÊÇ£¬ÓÉÓÚscAAVÈÝÁ¿ÓÐÏÞ£¬ÎªÁ˱£Ö¤³ö¶¾¼°¸ÐȾЧÂÊ£¬Ä¿µÄ»ùÒò¾¡Á¿Ñ¡Ôñ1kbÒÔÄÚ¡£

AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾
ͼ6 scAAV9-GFP¸ÐȾƤ²ã£¬ÈýÌì½á¹û



С½á

scAAV¾ßÓжàÖÖѪÇåÐÍ¡¢¿ìËÙ±í´ï¡¢Îȶ¨±í´ï¡¢ÃâÒßÔ­ÐÔÏà¶Ô½ÏµÍµÄÌØµã£¬Òò´ËÊÊÓÃÓÚ¶àÖÖÓ¦Óó¡¾°¡£

Copyright ? ÉϺ£AGÑÇÓ鼯ÍŹٷ½ÍøÕ¾ÉúÎï¼¼Êõ£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾    µØÖ·£ºÉϺ£ÊÐÆÖ¶«ÐÂÇø¹ú¼ÊÒ½Ñ§Ô°Çø×ÏÆ¼Â·908Ū19ºÅÂ¥

AGÑÇÓ鼯ÍÅ¡¤(Öйú)¹Ù·½ÍøÕ¾

µã»÷ѯ¼Û

¡¾ÍøÕ¾µØÍ¼¡¿